Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1,2-bis(4-isobutoxycarbonyloxymethyl-3,5-dioxopiperazin-1-yl)ethane
2. Mst 16
3. Mst-16
1. 98631-95-9
2. Mst 16
3. Mst-16
4. [4-[2-[4-(2-methylpropoxycarbonyloxymethyl)-3,5-dioxopiperazin-1-yl]ethyl]-2,6-dioxopiperazin-1-yl]methyl 2-methylpropyl Carbonate
5. Perazolin
6. R1308vh37p
7. Sobuzoxane (jan)
8. Ncgc00015954-02
9. Sobuzoxane [jan]
10. Sobuzoxano
11. Sobuzoxanum
12. Sobuzoxane [inn:jan]
13. Sobuzoxanum [inn-latin]
14. 4,4'-(1,2-ethanediyl)bis(1-iso-butoxycarbonyloxmethyl-2,6-piperazinedione)
15. Sobuzoxano [inn-spanish]
16. Brn 6031322
17. Unii-r1308vh37p
18. Perazolin (tn)
19. Sobuzoxane [mi]
20. Sobuzoxane [inn]
21. Lopac-s-4692
22. 1,2-bis(4-isobutoxycarbonyloxymethyl-3,5-dioxo-piperazin-1-yl)ethane
23. Sobuzoxane [mart.]
24. 4,4'-ethylenebis(1-(hydroxymethyl)-2,6-piperazinedione) Bis(isobutyl Carbonate) (ester)
25. Dsstox_cid_25203
26. Dsstox_rid_80747
27. Sobuzoxane [who-dd]
28. Dsstox_gsid_45203
29. Lopac0_001094
30. Schembl18416
31. Mls002153414
32. Chembl1256871
33. Dtxsid5045203
34. Chebi:32136
35. Hms2230c04
36. Hms3263k10
37. Hms3369l07
38. Tox21_110265
39. Tox21_501094
40. Mfcd00866498
41. Zinc22032147
42. Sobuzoxane, >=99% (hplc), Solid
43. Ccg-205171
44. Lp01094
45. Sdccgsbi-0051064.p002
46. Ncgc00015954-01
47. Ncgc00015954-03
48. Ncgc00015954-04
49. Ncgc00094367-01
50. Ncgc00094367-02
51. Ncgc00261779-01
52. Carbonic Acid, 1,2-ethanediylbis((2,6-dioxo-4,1-piperazinediyl)methylene)bis(2-methylpropyl) Ester
53. Smr001230790
54. Cas-98631-95-9
55. Eu-0101094
56. 1-n-trityl-imidazole-2-ylpropionicacid
57. D01404
58. F52515
59. S 4692
60. 631s959
61. A839107
62. Sr-01000075401
63. Sr-01000075401-2
64. Q27287640
65. 4,4'-(1,2-ethanediyl)bis(1-isobutoxycarbonyloxmethyl-2,6-piperazinedione)
66. 4,4'-(1,2-ethanediyl)bis(1-isobutoxycarbonyloxymethyl-2,6-piperazinedione)
67. (4,4'-(ethane-1,2-diyl)bis(2,6-dioxopiperazine-4,1-diyl))bis(methylene) Isobutyl Dicarbonate
68. [4-[2-[4-(2-methylpropoxycarbonyloxymethyl)-3,5-bis(oxidanylidene)piperazin-1-yl]ethyl]-2,6-bis(oxidanylidene)piperazin-1-yl]methyl 2-methylpropyl Carbonate
69. [4-[2-[4-(2-methylpropoxycarbonyloxymethyl)-3,5-dioxo-piperazin-1-yl]ethyl]-2,6-dioxo-piperazin-1-yl]methyl 2-methylpropyl Carbonate
70. Carbonic Acid [4-[2-[4-[[2-methylpropoxy(oxo)methoxy]methyl]-3,5-dioxo-1-piperazinyl]ethyl]-2,6-dioxo-1-piperazinyl]methyl 2-methylpropyl Ester
| Molecular Weight | 514.5 g/mol |
|---|---|
| Molecular Formula | C22H34N4O10 |
| XLogP3 | 2 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 12 |
| Rotatable Bond Count | 15 |
| Exact Mass | 514.22749329 g/mol |
| Monoisotopic Mass | 514.22749329 g/mol |
| Topological Polar Surface Area | 152 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 743 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Topoisomerase II Inhibitors
Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)
ABOUT THIS PAGE
A Sobuzoxane manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sobuzoxane, including repackagers and relabelers. The FDA regulates Sobuzoxane manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sobuzoxane API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Sobuzoxane supplier is an individual or a company that provides Sobuzoxane active pharmaceutical ingredient (API) or Sobuzoxane finished formulations upon request. The Sobuzoxane suppliers may include Sobuzoxane API manufacturers, exporters, distributors and traders.
click here to find a list of Sobuzoxane suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Sobuzoxane Drug Master File in Japan (Sobuzoxane JDMF) empowers Sobuzoxane API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Sobuzoxane JDMF during the approval evaluation for pharmaceutical products. At the time of Sobuzoxane JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Sobuzoxane suppliers with JDMF on PharmaCompass.
Sobuzoxane Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sobuzoxane GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Sobuzoxane GMP manufacturer or Sobuzoxane GMP API supplier for your needs.
A Sobuzoxane CoA (Certificate of Analysis) is a formal document that attests to Sobuzoxane's compliance with Sobuzoxane specifications and serves as a tool for batch-level quality control.
Sobuzoxane CoA mostly includes findings from lab analyses of a specific batch. For each Sobuzoxane CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sobuzoxane may be tested according to a variety of international standards, such as European Pharmacopoeia (Sobuzoxane EP), Sobuzoxane JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sobuzoxane USP).
LOOKING FOR A SUPPLIER?
